ATH434 currently in two trials for Multiple System Atrophy (a Parkinsonian disorder). Prelim 6 month readout for ATH434-202 trial in late stage MSA due this month.
Preclinical studies are promising, esp. when considered in tandem with the BioMUSE natural history study Alterity completed recently.
All time low is .3c, currently at .4c.
Not sure what the size of the market is, but it is woefully underserved; ergo, ATH could possibly be a multi-bagger if results are positive.
